MedTrace Logo

Glycosaminoglycan Scores as Early Detection Biomarkers in Bladder Urothelial Carcinoma

NCT05799456 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 106

Last updated 2023-04-05

No results posted yet for this study

Summary

Early detection of bladder cancer (BCa) is considered an effective strategy to curb mortality from the disease. However, current urinary biomarkers have insufficient specificity to warrant BCa screening. Urine free glycosaminoglycan profiles (or GAGomes) are promising noninvasive biomarkers of cancer metabolism. In this study, samples are obtained from patients with BCa and controls to compare the glycosaminoglycan profiles between groups.

Conditions

Interventions

DIAGNOSTIC_TEST

Free glycosaminoglycan profiling

Free glycosaminoglycan profiling (GAGome) analysis was performed at a single blinded central laboratory using commercial kits wherein the concentration (in µg/mL) of 17 chondroitin sulfate (CS), heparan sulfate (HS), hyaluronic acid (HA) disaccharides were detected and quantified using a UHPLC-MS/MS system.

Sponsors & Collaborators

  • Göteborg University

    collaborator OTHER

  • Jens Nielsen

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-10-01
Primary Completion
2023-02-28
Completion
2023-02-28

Countries

  • Sweden

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05799456 on ClinicalTrials.gov